Nuvalent (NUVL) to Release Quarterly Earnings on Thursday

Nuvalent (NASDAQ:NUVL) is expected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Nuvalent to announce earnings of ($1.44) per share and revenue of $0.2450 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same quarter in the prior year, the company posted ($1.18) earnings per share. On average, analysts expect Nuvalent to post $-6 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Nuvalent Stock Performance

Nuvalent stock opened at $123.96 on Wednesday. Nuvalent has a 12-month low of $71.13 and a 12-month high of $123.99. The firm has a market capitalization of $9.79 billion, a price-to-earnings ratio of -20.46 and a beta of 1.14. The firm has a 50 day moving average of $118.94 and a 200 day moving average of $108.44.

Insider Activity at Nuvalent

In other news, insider Henry E. Pelish sold 2,111 shares of the business’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $123.81, for a total value of $261,362.91. Following the transaction, the insider owned 63,493 shares of the company’s stock, valued at approximately $7,861,068.33. The trade was a 3.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO James Richard Porter sold 30,000 shares of the company’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $123.72, for a total transaction of $3,711,600.00. Following the transaction, the chief executive officer owned 324,879 shares of the company’s stock, valued at approximately $40,194,029.88. This represents a 8.45% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 90,471 shares of company stock valued at $9,762,529. Corporate insiders own 5.02% of the company’s stock.

Institutional Trading of Nuvalent

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. US Bancorp DE lifted its stake in Nuvalent by 10.0% in the 3rd quarter. US Bancorp DE now owns 2,070 shares of the company’s stock worth $179,000 after purchasing an additional 188 shares in the last quarter. Portland Investment Counsel Inc. bought a new stake in shares of Nuvalent in the fourth quarter worth about $201,000. FORA Capital LLC bought a new stake in shares of Nuvalent in the fourth quarter worth about $218,000. Tower Research Capital LLC TRC lifted its position in shares of Nuvalent by 23.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,142 shares of the company’s stock worth $240,000 after buying an additional 588 shares in the last quarter. Finally, CIBC Asset Management Inc purchased a new stake in shares of Nuvalent in the fourth quarter worth about $251,000. 97.26% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

NUVL has been the subject of a number of recent analyst reports. Wedbush lowered shares of Nuvalent from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $125.00 to $124.00 in a research report on Tuesday, June 9th. Truist Financial downgraded shares of Nuvalent from a “buy” rating to a “hold” rating and decreased their price objective for the company from $140.00 to $124.00 in a research report on Tuesday, June 9th. Sanford C. Bernstein cut shares of Nuvalent from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $172.00 to $124.00 in a research note on Wednesday, June 24th. Robert W. Baird set a $122.85 target price on shares of Nuvalent in a report on Tuesday, June 9th. Finally, Raymond James Financial lowered Nuvalent from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 9th. Four investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $127.73.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.